Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial

BACKGROUND: Raltegravir (RAL) has favorable tolerability and safety profile, with few and manageable drug interactions. The use of RAL 1200 mg once daily (qd) for first-line therapy is well established. We assessed efficacy and safety of RAL 1200 mg qd, as part of triple combined antiretroviral ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Nolwenn, Allavena, Clotilde, Katlama, Christine, Jobert, Alexandra, Molina, Jean-Michel, Cua, Eric, Bani-Sadr, Firouzé, Hocqueloux, Laurent, Duvivier, Claudine, Merrien, Dominique, Hikombo, Hitoto, André-Garnier, Elisabeth, Gaultier, Aurélie, Raffi, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760827/
https://www.ncbi.nlm.nih.gov/pubmed/35033092
http://dx.doi.org/10.1186/s12981-022-00428-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760827/
https://www.ncbi.nlm.nih.gov/pubmed/35033092
http://dx.doi.org/10.1186/s12981-022-00428-5

Ejemplares similares